Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.

Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association1 Sept 2006Cited by 96 (Europe PMC)

PMID17039422DOI10.1055/s-2006-924230PepBankPUB-17039422

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, adding liraglutide significantly reduced fasting serum glucose over 5 weeks.
In plain wordsIn adults with type 2 diabetes taking metformin, adding liraglutide lowered fasting blood sugar more than metformin alone.
Peptide
Liraglutide
Outcome
DecreaseFasting serum glucose
Study
n: not reported in source
Comparator
Metformin alone
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 to 2 mg once daily, weekly titration · 5 weeksAs given in this study (human).
Measurements
Fasting serum glucose change
−3.9 mM
metformin plus liraglutide
Source sentences
Summary
Liraglutide added to metformin monotherapy was associated with a significant reduction in fasting serum glucose (FSG) (-3.9 mM -4.9; -2.9) (primary objective), and HbA1c levels (-0.8% -1.2; -0.4).
1 context sentence(design, population, supporting numbers)
Summary · context
144 type 2 diabetic subjects on metformin treatment (1000 mg BID) were randomised to 5 weeks of treatment (double-blind) with metformin plus liraglutide, liraglutide or metformin, or metformin plus glimepiride (open label).
Report a problemFND-1703942201
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, adding liraglutide significantly reduced HbA1c over 5 weeks.
In plain wordsIn adults with type 2 diabetes taking metformin, adding liraglutide lowered HbA1c more than metformin alone.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Metformin alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 to 2 mg once daily, weekly titration · 5 weeksAs given in this study (human).
Measurements
HbA1c change
−0.8%
metformin plus liraglutide
Source sentences
Summary
Liraglutide added to metformin monotherapy was associated with a significant reduction in fasting serum glucose (FSG) (-3.9 mM -4.9; -2.9) (primary objective), and HbA1c levels (-0.8% -1.2; -0.4).
1 context sentence(design, population, supporting numbers)
Summary · context
144 type 2 diabetic subjects on metformin treatment (1000 mg BID) were randomised to 5 weeks of treatment (double-blind) with metformin plus liraglutide, liraglutide or metformin, or metformin plus glimepiride (open label).
Report a problemFND-1703942202
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide plus metformin reduced fasting serum glucose more than metformin plus glimepiride.
In plain wordsIn adults with type 2 diabetes, liraglutide plus metformin lowered fasting blood sugar more than metformin plus glimepiride.
Peptide
Liraglutide
Outcome
DecreaseFasting serum glucose versus metformin plus glimepiride
Study
n: not reported in source
Comparator
Metformin plus glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 to 2 mg once daily, weekly titration · 5 weeksAs given in this study (human).
Measurements
Fasting serum glucose difference
−1.2 mM
vs metformin plus glimepiride
Source sentences
Summary
Furthermore, liraglutide in combination with metformin vs. metformin plus glimepiride significantly reduced FSG (-1.2 mM -2.2; -0.2).
1 context sentence(design, population, supporting numbers)
Summary · context
144 type 2 diabetic subjects on metformin treatment (1000 mg BID) were randomised to 5 weeks of treatment (double-blind) with metformin plus liraglutide, liraglutide or metformin, or metformin plus glimepiride (open label).
Report a problemFND-1703942203
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, body weight was significantly lower with liraglutide plus metformin than with metformin plus glimepiride.
In plain wordsIn adults with type 2 diabetes, body weight was lower with liraglutide plus metformin than with metformin plus glimepiride.
Peptide
Liraglutide
Outcome
DecreaseBody weight versus metformin plus glimepiride
Study
n: not reported in source
Comparator
Metformin plus glimepiride
Outcome group
Body weight · Metabolic and weight
Studied dose
0.5 to 2 mg once daily, weekly titration · 5 weeksAs given in this study (human).
Measurements
Body weight difference
−2.9 kg
vs metformin plus glimepiride
Source sentences
Summary
In addition, body weight was significantly lower in the metformin plus liraglutide vs. the metformin plus glimepiride group (-2.9 kg -3.6; -2.1).
1 context sentence(design, population, supporting numbers)
Summary · context
144 type 2 diabetic subjects on metformin treatment (1000 mg BID) were randomised to 5 weeks of treatment (double-blind) with metformin plus liraglutide, liraglutide or metformin, or metformin plus glimepiride (open label).
Report a problemFND-1703942204
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, no biochemically confirmed hypoglycaemia occurred with liraglutide treatment.
In plain wordsIn adults with type 2 diabetes, liraglutide caused no confirmed low blood sugar episodes.
Peptide
Liraglutide
Outcome
No significant changeHypoglycaemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.5 to 2 mg once daily, weekly titration · 5 weeksAs given in this study (human).
Source sentences
Summary
There were no biochemically confirmed episodes of hypoglycaemia with liraglutide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
144 type 2 diabetic subjects on metformin treatment (1000 mg BID) were randomised to 5 weeks of treatment (double-blind) with metformin plus liraglutide, liraglutide or metformin, or metformin plus glimepiride (open label).
Report a problemFND-1703942205
06HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, nausea was the most frequently reported adverse event with liraglutide and was transient.
In plain wordsIn adults with type 2 diabetes, nausea was the most common side effect of liraglutide and passed quickly.
Peptide
Liraglutide
Outcome
Not applicableNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.5 to 2 mg once daily, weekly titration · 5 weeksAs given in this study (human).
Source sentences
Summary
Nausea was the most frequently reported adverse event following liraglutide therapy, it was transient in nature
1 context sentence(design, population, supporting numbers)
Summary · context
144 type 2 diabetic subjects on metformin treatment (1000 mg BID) were randomised to 5 weeks of treatment (double-blind) with metformin plus liraglutide, liraglutide or metformin, or metformin plus glimepiride (open label).
Report a problemFND-1703942206
07HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, nausea with liraglutide led to withdrawal of only 4% of subjects.
In plain wordsIn adults with type 2 diabetes, nausea led only 4% of people on liraglutide to stop treatment.
Peptide
Liraglutide
Outcome
Not applicableWithdrawal due to nausea
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
0.5 to 2 mg once daily, weekly titration · 5 weeksAs given in this study (human).
Measurements
Withdrawal
4%
liraglutide
Source sentences
Summary
and led to withdrawal of only 4% of the subjects.
1 context sentence(design, population, supporting numbers)
Summary · context
144 type 2 diabetic subjects on metformin treatment (1000 mg BID) were randomised to 5 weeks of treatment (double-blind) with metformin plus liraglutide, liraglutide or metformin, or metformin plus glimepiride (open label).
Report a problemFND-1703942207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT01511172

Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 145Aug 2002 to Dec 2002

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 25 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.